DLBCL是一组具显著临床异质性肿瘤，EBV+DLBCL累及年轻患者则具更强侵袭性和更高致死率。EBV在B细胞终末分化阶段进行复制发挥致瘤作用，Blimp1是该阶段重要转录因子。研究发现中国人DLBCL存在高频Blimp1基因突变，且与预后密切相关。癌基因LMP1是EBV相关肿瘤潜伏感染的客观指标，能以多种机制促进肿瘤形成和发展，LMP1在DLBCL中是否通过下调Blimp1基因而增强其致瘤性？两基因间的相互作用机制及表达差异和突变模式能否有效预测肿瘤预后？拟用基因芯片技术筛选不同分型间差异表达的Blimp1、LMP1基因；染色质免疫共沉淀-定量RT-PCR验证芯片检测结果，PCR联合直接测序法检测上述基因突变模式； MSPCR方法检测两基因启动子区甲基化水平，研究两基因作用机制。应用siRNA干扰技术分析两基因生物学功能，为患者提供个体化治疗方案，提高和监控疗效，阐述肿瘤发生机制奠定基础

Diffuse large B cell lymphoma is a group of a significant clinically heterogeneous tumor.EBV positive DLBCL tumor involved younger patient has highly aggressive behavior and highly mortality, but not to be classify, now. EB viral complete replicate cycle in B lymphocyte into plasma cell differentiation,Blimp1 transcript is an important regulator factor in B lymphocyte into plasma cell differentiation. Study has discovered DLBCL with high-frequency Blimp1 gene mutation which associated with poor prognosis in China. EBV participate tumorigenesis throughout to dowm regulator Blimp1 transcript is still unclear, Different molecular subtype DLBCL existing Blimp1 gene differential expression and associated signaling pathway molecular differential expression whether or not has not been systematically studied in Xinjiang.Combining detection Blimp1 and LMP1 gene mutation and differential expression possibly effective predict the tumor's prognosis;we will accurately category molecular subtypes using gene chip technology and screen Blimp1 and LMP1 gene differential expression between different subtypes DLBCL; We will validate the differential expression gene such as Blimp1 and LMP1 gene in mRNA level using Chromatin immunoprecipitation coprecipitation - real-time quantitative PCR technology, than we will detect the differential gene above metioned using fluorescence quantitative qRT-PCR method in mRNA expression levels, than we will detect Blimp1 and LMP1 gene mutation with PCR combined direct sequencing method, MSPCR method will detect two gene promoter methylation levels, and anlysis Blimp1 and LMP1 biology function with siRNA method, than we will combine clinicopathological factors to establish a multi-gene prognostic predict model, and to lay the foundation for the implementation of individualized treatment, improve and monitor the therapy efficacy, reveal oncogenic pathways that are used differentially by the DLBCL subtypes, reinforcing the view that they represent pathogenetically distinct diseases.